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‘Click cyclic ADP-ribose’: a neutral second
messenger mimic†
Joanna M. Swarbrick,a Richard Graeﬀ,b Clive Garnham,c Mark P. Thomas,a
Antony Galionec and Barry V. L. Potter*b
Analogues of the potent Ca2+ releasing second messenger cyclic
ADP-ribose (cADPR) with a 1,2,3-triazole pyrophosphate bioisostere
were synthesised by click-mediated macrocyclisation. The ability to
activate Ca2+ release was surprisingly retained, and hydrolysis of
cADPR by CD38 could also be inhibited, illustrating the potential of
this approach to design drug-like signalling pathway modulators.
Intracellular Ca2+ plays a key role in many processes including cell
division, muscle contraction, cell death and fertilisation.1 The spatial
and temporal release of Ca2+ within the cell is controlled by second
messengers. In contrast to the now well characterized IP3,
2 the three
Ca2+ mobilizing nucleotides adenosine 50-diphosphate ribose
(ADPR), cyclic-ADPR (cADPR), and nicotinic acid adenine dinucleo-
tide phosphate (NAADP) are relatively new secondmessengers whose
specialised roles are only just emerging. Currently, the only examples
of neutral, active, drug-like molecules able to modulate one of these
critical pathways are the NAADP signalling probe ‘Ned-19’, that was
identified by virtual screening,3 and very recently SAN2589 and
SAN4825, identified by high-throughput screening, and specific to
the cardiac cADPR signalling pathway.4
In humans cADPR (1, Fig. 1),5 like ADPR and NAADP, is formed
from nicotinamide adenine dinucleotide by CD38, a multifunctional
ADP-ribosyl cyclase6 involved in disease states including AIDs,
leukaemia, diabetes and inflammation.7 Two opposing orientations
of CD38 have been reported, allowing the catalytic domain to be
both extra- or intracellular and resolving a long-standing topological
paradox.8 Ca2+ release by cADPR occurs at the ryanodine receptor
and may require accessory proteins; the mechanism remains con-
troversial.9 The cADPR signalling pathway is thus in pressing need of
new modulators for chemical biological intervention and as
prototype therapeutic candidates. However, its charged pyropho-
sphate motif is unattractive in molecules for medicinal and clinical
development, due to obvious diﬃculties with membrane perme-
ability and stability. Furthermore, cADPR is readily hydrolysed in
both neutral aqueous solution and under physiological conditions.10
Despite the preparation of numerous cADPR analogues,11 previous
work has failed to address the critical issue of the pyrophosphate.
Furthermore, analogue synthesis has been limited in scope, yield and
number by either the substrate specificity of Aplysia californica
cyclase12 or because of arduous multi-step synthetic routes.13 While
introduction of a third phosphate maintains potent agonist activity,14
the pyrophosphate region of cADPR is demonstrably sensitive to
conservative modifications: a methylenebisphosphonate substitution
is less active15 and sulphur or selenium-substituted pyrophosphates
demonstrate contrasting activities between diastereoisomers in
ether-substituted analogues.16 Alkylating the pyrophosphate has
been used to generate ‘‘caged cADPR’’ and derivatives as tools
with improved membrane permeability, but such analogues
themselves are biologically inactive.17 Such approaches do not
address hydrolysis of the pyrophosphate bond18 and the dra-
matic impact on activity observed with such minor alterations
seems to suggest that complete removal of the charged motif
would likely be fruitless for the generation of active compounds.
Pyrophosphates are one of themost challenging functionalities to
replace in the generation of biologically active, drug-like com-
pounds.19 They are negatively charged at physiological pH20 and
this usually corresponds to positively charged or electron poor
residues in a binding counterpart, a consideration for any neutral
replacement.21 1,2,3-Triazoles are neutral, but possess nitrogen lone
Fig. 1 Structure of cADPR, cIDPR and 1,4-triazole analogues 3 and 4.
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pairs thatmay supply electron density during binding.While present
in some linear inhibitors22 and carbohydrate analogues,23 no such
substitution has been explored in any cyclic nucleotide.
To avoid instability and remove the partial positive charge at N1,
we chose an N1-cyclic inosine 50-diphosphate ribose (cIDPR, 2)24
scaﬀold. This 6–NH2 - 6QO substitution in cADPR led to an
analogue that inhibits hydrolysis of cADPR by CD3825 and is an
agonist for Ca2+ release in permeabilized T-cells with essentially
equivalent potency to cADPR.24 Therefore, we designed a suitable
N1-ribosylated inosine26 precursor to explore Huisgen 1,3-dipolar
cycloaddition.27
A 50-azido group was installed on 20,30-O-isopropylidene
adenosine (5, Scheme 1), under Mitsunobu-like conditions.28 The
azide was installed prior to the 8-bromo substituent that is required to
promote N1-ribosylation,26 to circumvent concomitant nucleophilic
substitution of the 8-Br generating an unwanted 8-N3 product
with an undesirable second site for click cyclisation. Subse-
quently, the 8-Br substituent was installed by treatment of 6
with Br2 in dioxane–NaOAc buffer at pH 4 to generate protected
50-azido-50-deoxy-8-bromoadenosine 7. This was followed by
conversion to the corresponding 8-bromoinosine 8 by treatment
with a large excess of sodium nitrite in aqueous acetic acid.
50-Azido-50-deoxy-20,30-O-isopropylidene-8-bromoinosine 8 was
coupled to the tri-O-acetyl protected ‘‘northern’’ ribose unit in 91%
yield. No evidence of competing O-6 alkylation was observed. The
three acetyl esters were removed using methanolic ammonia to
generate triol 10 and the 200,300-diol was selectively reprotected as an
isopropylidene ketal in intermediate 11. Initial attempts to introduce
a 500-O-propargyl ether to 11 were not successful. Deprotonation with
NaH led to rapid decomposition of the starting material and
deprotonation with DBU followed by addition of propargyl-chloride
recovered only unreacted starting material. Upon treatment of 11
with KOH inMeCN, a white precipitate was observed and no further
reaction occurred. Optimising the solvent conditions to dioxane–
toluene (2 :1 v/v) in which the anion of 11 remained in solution,
followed by addition of the more reactive electrophile propargyl-
bromide generated the desired ether 12 in moderate yield.
In initial attempts to promote click cyclisation, using in situ
reduction of Cu(II), a dilute solution of 12 was added to a solution of
copper sulfate and sodium ascorbate by syringe pump, but after 72
hours no reaction was observed. In contrast, direct addition of Cu(I)I
to a 1 mg mL1 degassed solution of 12 and diisopropylethylamine
in THF27b followed by 16 h reflux generated a single product.
1H-NMR spectroscopy of the crude material revealed that an
exceedingly clean conversion had taken place, characterised by a
new singlet at 7.15 ppm indicative of a 1,4-disubstituted-1,2,3-triazole
and disappearance of the alkynyl proton (d = 2.46 ppm). No evidence
of any intermolecular reaction was observed. Treatment of
1,4-disubstituted triazole 13 with aq. TFA then removed both
isopropylidene ketal protecting groups to generate 14 (Scheme 2).
The resulting 8-bromotriazole derivative 14 is insoluble in
D2O. However, reduction of the 8-bromo substituent with Pd/C
under an atmosphere of H2 generated the water-soluble cyclic
triazole 3. Treatment of 14 with sodium azide in DMF generated
the 8-azidotriazole 15, also insoluble in aqueous media.
Reduction of the 8-azido to the 8-amino group by hydrogenation
generated a second water soluble analogue 4. No decomposition
of the cyclic 1,4-disubstituted triazole analogues was observed
during deprotection with TFA or at elevated reaction tempera-
tures (70 1C), suggesting that they are chemically stable.
The ability of 3 and 4 to inhibit the enzyme activity of CD38 was
assessed. Both novel compounds inhibit hydrolysis of cADPR by
CD38, suggesting that they block entry of cADPR into the binding
pocket. Non-substituted 3 is a slightly poorer inhibitor (IC50 396 mM,
Fig. 2) than the parent template cIDPR (IC50 260 mM, ref. 25). However,
introduction of the 8-amino substituent in 4 improves inhibition (IC50
185 mM). The similarity in inhibition shown by cIDPR, 3 and 4
suggests that the ability of these analogues to enter the binding
pocket is surprisingly not reduced by the pyrophosphate -
1,2,3-triazole substitution. In fact, the reduction in macrocycle
flexibility caused by the planar triazole may even reduce the overall
size of the ligand, making it easier for 3 and 4 to enter the binding
pocket.
To rationalise the observed activity, 3 and 4 were each
docked 25 times into the co-crystal structure of CD38 and
cIDPR25 with the cIDPR ligand removed. The majority of the
docked ligands had the same pose (Fig. 3a and b, Fig. S1, ESI†)
in which the ‘‘northern’’ ribose of the ligand overlays that of the
Scheme 1 Synthesis of linear precursor suitable for click cyclisation. Reagents
and conditions (i) (a) DPPA, DBU; (b) NaN3, TBAI, 15-crown-5, 100%; (ii) Br2, pH 4,
99%; (iii) NH3, MeOH, 81%; (iv) Me2C(OMe)2, acetone, pTsOH, 93%.
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crystal structure ligand almost perfectly and the 1,4-disubstituted
triazole lies between the two phosphate groups. The inosine ring is
slightly tilted and the ‘‘southern’’ ribose does not overlay its crystal
structure counterpart, most likely a consequence of the planar
triazole ring reducing flexibility in the macrocycle.
The bioactive conformation of cIDPR bound to CD38 reveals
that the hydroxyl group of Ser126 and the e-NH group of Arg127
form H-bonds to the pyrophosphate (Fig. S2, ESI†). In the
simulated protein–ligand complex of 3 the hydroxyl group of
Ser126 is too far from the triazole to form an H-bond but the
e-NH of Arg127 forms an H-bond to N3 and the terminal NH2
forms two water-mediated H-bonds to N2 and N3 of the triazole
(Fig. 3c). This suggests that the triazole motif is able to mimic
the interaction of the pyrophosphate with the binding site
to some extent. In addition, the docking of 4 predicts that its
8-NH2 group could H-bond to Asp-155, rationalising the
improved inhibitory activity of 4 vs. 3 observed experimentally.
This correlates well with a similar effect in CD38 for 8-NH2-
cIDPR vs. cIDPR, recently observed crystallographically in an
8-NH2-cIDPR:CD38 complex
29 (Fig. S3, ESI†) and implies a
likely similar binding mode for the two types of analogue,
supporting the overall concept of pyrophosphate replacement.
Importantly, cIDPR (2), 3 and 4 were also examined for Ca2+
releasing ability in sea urchin egg homogenate (SUH). cIDPR (2)
is an agonist, but ca. 1000 fold weaker than cADPR, high-
lighting diﬀerences at this invertebrate receptor, compared to
its mammalian T-cell activity.24 Triazole 3 is also substantially
weaker than cADPR, but releases Ca2+ only slightly less potently
than the more relevant parent ligand 2, demonstrating that 3 acts
as an agonist at intracellular Ca2+ stores (Fig. 4). Interestingly,
the 8-NH2-substituted 4 showed no Ca
2+ releasing activity
(data not shown), in keeping with previous observations that
the 8-H- 8-NH2 substitution may be a critical agonist/antagonist
switch.30 Thus, it may be possible to selectively engineer the activity
of analogues towards CD38.
In summary, we have developed a concise synthetic route to a
new class of neutral cADPR analogue that is still active at two protein
targets. Macrocyclisation was achieved by a clean, high yielding
‘click’ reaction which simultaneously formed the 1,2,3-triazole
pyrophosphate bioisostere. The uncharged analogues inhibit
CD38 hydrolysis of cADPR with a similar potency to that of the
parent molecule, cIDPR. Triazole analogue 3, like 2, is also active
at the cADPR receptor and mobilises Ca2+. These are the first
active, neutral cADPR analogues with complete pyrophosphate
replacement and represent leads for simplified cADPR-based cell
signalling modulators. Taken together, their chemical and bio-
logical stability, uncharged nature and the surprising retention
of activity observed upon complete pyrophosphate substitution
point towards CD38 and the cADPR receptor as potentially
druggable targets.
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